162 related articles for article (PubMed ID: 15790600)
1. Endocrine approaches in the therapy of prostate carcinoma.
d'Ancona FC; Debruyne FM
Hum Reprod Update; 2005; 11(3):309-17. PubMed ID: 15790600
[TBL] [Abstract][Full Text] [Related]
2. Secondary hormonal therapy.
Smith DC
Semin Urol Oncol; 1997 Feb; 15(1):3-12. PubMed ID: 9050134
[TBL] [Abstract][Full Text] [Related]
3. Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer.
Shaw G; Oliver RT
Surg Oncol; 2009 Sep; 18(3):275-82. PubMed ID: 19269165
[TBL] [Abstract][Full Text] [Related]
4. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
5. Endocrine therapy for prostate cancer.
Damber JE
Acta Oncol; 2005; 44(6):605-9. PubMed ID: 16165920
[TBL] [Abstract][Full Text] [Related]
6. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
[TBL] [Abstract][Full Text] [Related]
7. Advances in the management of metastatic androgen-independent prostate cancer.
Laber DA; Goetz H K; Bhupalam L
J Ky Med Assoc; 2006 Feb; 104(2):65-9. PubMed ID: 16594572
[TBL] [Abstract][Full Text] [Related]
8. Endocrine treatment of prostate cancer: standard treatment and new perspectives.
Boccardo F; Pace M
In Vivo; 1993; 7(5):423-4. PubMed ID: 8110985
[TBL] [Abstract][Full Text] [Related]
9. Maximal androgen blockade for advanced prostate cancer.
Klotz L
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
[TBL] [Abstract][Full Text] [Related]
10. Secondary hormonal therapy for advanced prostate cancer.
Lam JS; Leppert JT; Vemulapalli SN; Shvarts O; Belldegrun AS
J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
[TBL] [Abstract][Full Text] [Related]
11. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
Vis AN; Schröder FH
BJU Int; 2009 Nov; 104(9):1191-7. PubMed ID: 19624596
[TBL] [Abstract][Full Text] [Related]
12. Gn-RH agonists in the treatment of prostatic carcinoma.
Vacher P
Biomed Pharmacother; 1995; 49(7-8):325-31. PubMed ID: 8562857
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
Milecki P; Kwias Z; Martenka DJ
Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
[TBL] [Abstract][Full Text] [Related]
14. Optimal hormonal therapy for advanced prostatic carcinoma.
Goktas S; Crawford ED
Semin Oncol; 1999 Apr; 26(2):162-73. PubMed ID: 10597727
[TBL] [Abstract][Full Text] [Related]
15. The benefits of early androgen blockade.
Maroni PD; Crawford ED
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789
[TBL] [Abstract][Full Text] [Related]
16. Current status and prospects of androgen depletion therapy for prostate cancer.
Akaza H
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):293-302. PubMed ID: 18471787
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma.
Rozhansky F; Chen MH; Cox MC; Dahut W; Figg WD; D'Amico AV
Cancer; 2006 Jan; 106(1):63-7. PubMed ID: 16333854
[TBL] [Abstract][Full Text] [Related]
18. [Innovations in hormonal treatment for locally advanced and/or metastatic prostate cancer].
Audenet F; Rouprêt M; Tombal B
Prog Urol; 2011 May; 21 Suppl 3():S96-101. PubMed ID: 21616448
[TBL] [Abstract][Full Text] [Related]
19. New drugs in prostate cancer.
Armstrong AJ; Carducci MA
Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
[TBL] [Abstract][Full Text] [Related]
20. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
